Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs New England healthcare system

Journal of the American Geriatrics Society

Volumn 57, Issue 11, 2009, Pages 1997-2003

  Hernandez, Rohini K ^a,b   Farwell, Wildon ^a,c   Cantor, Michael D ^d   Lawler, Elizabeth V ^a,b,c  

^a VA BOSTON HEALTHCARE SYSTEM   (United States)

^b BOSTON UNIVERSITY   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease; Bradycardia; Cholinesterase inhibitors; Dementia

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

AGED; ARTICLE; ARTIFICIAL HEART PACEMAKER; BRADYCARDIA; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEMENTIA; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FALLING; FEMALE; HEALTH CARE SYSTEM; HEART RATE; HUMAN; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; POPULATION BASED CASE CONTROL STUDY; PROSPECTIVE STUDY; RISK; SYNCOPE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; UNITED STATES; VETERAN;

ALZHEIMER DISEASE; BRADYCARDIA; CHOLINESTERASE INHIBITORS; CROSS-SECTIONAL STUDIES; DEMENTIA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GALANTAMINE; HEART RATE; HOSPITALS, VETERANS; HUMANS; INCIDENCE; INDANS; MASSACHUSETTS; NOOTROPIC AGENTS; PHENYLCARBAMATES; PIPERIDINES; RISK; VETERANS;

EID: 70350459432     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2009.02488.x     Document Type: Article

References (20)

1. Ellis JM. Cholinesterase inhibitors in the treatment of dementia. JAOA 2005 105 : 145 158.
2. Cummings JL. Use of cholinesterase inhibitors in clinical practice. Evidence-based recommendations. Am J Geriatr Psychiatry 2003 11 : 131 145.
3. McCain KR, Sawyer TS, Spiller HA. Evaluation of centrally acting cholinesterase inhibitor exposures in adults. Ann Pharmacother 2007 41 : 1632 1637.
4. Dhein S, van Koppen CJ, Brodde OE. Muscarinic receptors in the mammalian heart. Pharmacol Res 2001 44 : 161 182.
5. Wang J, Wang X, Irnaten M et al. Endogenous acetylcholine and nicotine activation enhances GABAergic and glycinergic inputs to cardiac vagal neurons. J Neurophysiol 2003 89 : 2473 2481.
6. Bordier P, Garrigue S, Barold SS et al. Significance of syncope in patients with Alzheimer's disease treated with cholinesterase inhibitors. Europace 2003 5 : 429 431.
7. Shepherd G, Klein-Schwartz W, Edwards R. Donepezil overdose: A tenfold dosing error. Ann Pharmacother 1999 33 : 812 815.
8. Fisher AA, Davis MW. Prolonged QT interval, syncope, and delirium with galantamine. Ann Pharmacother 2008 42 : 278 283. Epub 2008 Jan 8.
9. Jones PM, Soderman RM. Intra-operative bradycardia in a patient with Alzheimer's disease treated with two cholinesterase inhibitors. Anaesthesia 2007 62 : 201.
10. Ballard C, Lane R, Barone P et al. Cardiac safety of rivastigmine in Lewy body and Parkinson's disease dementias. Int J Clin Pract 2006 60 : 639 645.
11. Schneider LS, Olin JT, Lyness SA et al. Eligibility of Alzheimer's disease clinic patients for clinical trials. J Am Geriatr Soc 1997 45 : 923 928.
12. Gill SS, Anderson GM, Fischer HD et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: A population-based cohort study. Arch Intern Med 2009 169 : 867 873.
13. Pratt RD, Perdomo CA, Surick IW et al. Donepezil: Tolerability and safety in Alzheimer's disease. Int J Clin Pract 2002 56 : 710 717.
14. Doody RS, Geldmacher DS, Gordon B et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001 58 : 427 433.
15. Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001 57 : 489 495.
16. Jackson S, Ham RJ, Wilkinson D. The safety and tolerability of donepezil in patients with Alzheimer's disease. Br J Clin Pharmacol 2004 58 : 1 588.
17. Doody RS, Dunn JK, Clark CM et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001 12 : 295 300.
18. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975 12 : 189 198.
19. Messerli FH, Bangalore S. Resting heart rate and cardiovascular disease: The beta-blocker-hypertension paradox. J Am Coll Cardiol 2008 51 : 330 331 author reply 331-2.
20. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol 2008 52 : 1482 1489.